Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00747318 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
A Phase 3 study of Asthma, sponsored by SkyePharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT00747318: Completed Phase 3 study of Asthma, sponsored by SkyePharma.
NCT00747318 is a Phase 3 study of Asthma that has completed, run by SkyePharma. The registered enrollment target is 280 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00747318, a Phase 3 study of Asthma, has completed, sponsored by SkyePharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005.
Conditions Studied
Interventions
- DRUG SKP FlutiForm HFA pMDI
Study Locations (20)
Lima Province
- Investigational site - Lima
- Investigational site - Lima
- Investigational site - Lima
- Investigational site - Lima
- Investigational site - Lima
Oregon
- Investigational Site - Medford
- Investigational Site - Portland
Rhode Island
- Investigational Site - East Providence
- Investigational Site - Providence
Arizona
- Investigational Site - Scottsdale
California
- Investigational Site - Orange County
Colorado
- Investigational Site - Colorado Springs
Florida
- Investigational Site - Valrico
North Carolina
- Investigational Site - Elizabeth City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00747318
The ClinicalTrials.gov registry entry for NCT00747318 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (82% lower). The listed sponsor is SkyePharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which SKP FlutiForm HFA pMDI is the first listed.
NCT00747318 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Lima Province, Oregon, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00747318 about?
NCT00747318 is a clinical study titled "A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005". The objective of this study is to assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005.
What is the current status of trial NCT00747318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 280 participants. The study started on 2008-09. Estimated completion is 2010-06.
What conditions does trial NCT00747318 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00747318?
The interventions under investigation include: SKP FlutiForm HFA pMDI (DRUG).
Who is sponsoring clinical trial NCT00747318?
This trial is sponsored by SkyePharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00747318 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.